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Abstract
Immunoconjugates, including antibody-drug conjugates and Fc-conjugates, represent a rapidly
growing class of therapeutics undergoing clinical development. Despite their growing popularity,
the high intrinsic heterogeneity of immunoconjugates often complicates the development process
and limits their widespread application. In particular, immunoconjugate charge variants exhibit
markedly different colloidal stabilities, solubilities, pharmacokinetics and tissue distributions.
Charge variants arise spontaneously due to degradation and, depending on the type of drug, linker
and conjugation site, through drug conjugation. Electrostatic changes in naked antibodies often
result in poor performance characteristics, and therefore charge alterations due to degradation are
critical to control. Charge properties are expected to be equally important to producing well-
behaved ADCs. Charge-based methods of analysis, such as isoelectric focusing and ion exchange
chromatography, are capable of probing the underlying complexities within immunoconjugate
drug products. Despite the utility of these methods, there are only a few published reports of
charge-based assays applied to immunoconjugates. In the present study, we sought to identify the
effects of chemical conjugation on the electrostatic properties of Fc-conjugates. In order to
minimize the effects of post-translational modifications (e.g. deamidation), a single Fc charge
variant was isolated prior to conjugation of a fluorescent probe, Alexa Fluor 350, to the side
chains of lysine residues. The resulting Fc-conjugates were assessed by a variety of analytical
techniques, including isoelectric focusing and ion exchange chromatography, to determine their
charge properties.
Introduction
Immunoconjugates, including antibody-drug conjugates (ADCs) and Fc conjugates,
represent a growing segment of the therapeutic candidates undergoing development 1. ADCs
combine the targeting specificity of monoclonal antibodies (mAbs) with the highly potent
cytotoxic properties of small molecules for the treatment of cancer. A linker is used to
covalently attach the cytotoxin to the mAb. Despite recent advances in the engineering,
design and selection of ADCs 1, a major challenge remains intrinsic heterogeneity, which
can have a profound effect on the pharmacokinetics and tissue distribution of ADCs 2 as
well as the physicochemical stability of the formulation 3.
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Biotherapeutics are inherently complex systems. During manufacturing, heterogeneities can
be introduced due to enzymatic processing or spontaneous degradation 4-5. Monoclonal
antibodies are subject to post-translational modification, such as variable glycosylation, and
routes of degradation, including deamidation, isomerization, oxidation, fragmentation,
pyroglutamate formation and aggregation 4, 6. These chemical and physical alterations often
change the surface charge of mAbs 4-5. Chemical conjugation, particularly when linking to
lysine, modifies the electrostatic properties of the mAb surface and introduces further
complexities. Monoclonal antibodies often have 40-60 lysine residues and chemical
conjugation results in a heterogeneous mixture consisting of unconjugated mAbs and mAbs
conjugated with a variable number of cytotoxins in random combinations at different sites
on the antibody. Furthermore, chemical conjugation can potentially alter the mAbs
hydrophobicity, charge, polarity, pharmacokinetics 7, and thermostability 3, 8. The inherent
heterogeneity of ADCs remains a prominent challenge in characterizing their in vivo
properties during development 2.
To control heterogeneity, robust and reproducible manufacturing processes and appropriate
analytical methods are required. Analytical characterization plays an important role in
ensuring product integrity and manufacturing consistency 4, which are essential for
demonstrating safety and efficacy to the FDA and other regulatory authorities. However, the
heterogeneity of ADCs makes the analytical characterization particularly challenging 9.
Selection of appropriate analytical techniques depends on the properties of the linker, the
drug and the choice of attachment site 9. Analytical methods commonly used to assess the
physicochemical properties of ADCs include mass spectrometry, chromatography, and
electrophoresis. Here, we invoke a combination of these techniques to characterize the
charge-based heterogeneity of a model immunoconjugate system. The system consists of
IgG1 Fc conjugated with a fluorescent molecule, Alexa Fluor 350, via reaction with the
solvent accessible lysine residues.
Experimental Procedures
Materials
Chemicals were obtained from Sigma-Aldrich unless otherwise noted. Deionized water (18
MΩ cm) obtained from a Barnstead NANOpure Infinity water purification system was used
to prepare all solutions.
Methods
Expression and purification of IgG1 Fc—IgG1 Fc was expressed in a modified strain
of SMD1168 Pichia pastoris and purified by protein G affinity chromatography as
previously described 10-11. Fc was buffer-exchanged into mobile phase A (10 mM Tris HCl,
pH 9.0) using 10K MWCO Amicron Ultra-15 Centrifugal Filter Units (Millipore, Bedford,
MA) and further purified via strong anion-exchange (SAX) chromatography. Approximately
0.5 mg of protein was loaded onto a Dionex ProPac SAX-10, 4 × 250 mm column
(Sunnyvale, CA). Separation was achieved on a Shimadzu Prominence LC system (Tokyo,
Japan) operated at 1 mL/min with a gradient of 99% A (10 mM Tris HCl, pH 9.0), 1% B (10
mM Tris HCl, 1 M NaCl, pH 9.0) to 90% A and 10% B over 25 min, followed by 1% A and
99% B over 1 min, which was then maintained for 5 min to wash the column. The column
effluent was monitored at 280 nm. Fractions from 19 to 21 min were pooled (Figure S1,
Supporting Information), concentrated and buffer-exchanged into phosphate buffer (50 mM
sodium phosphate, 50 mM NaCl, pH 7.3). The Fc concentration was determined by UV
absorbance at 280 nm (molar extinction coefficient for Fc heavy chain = 35,785 M−1 cm−1).
Theoretical molar extinction coefficient and isoelectric point (pI) for IgG1 Fc were
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determined using the ProtParam tool within ExPaSy Proteomics Server of the Swiss Institute
of Bioinformatics (http://www.expasy.ch/tools/protparam.html) 12.
Synthesis of Fc-conjugates—Fc-conjugates were prepared at various dye-to-antibody
ratios (DAR) by reacting Alexa Fluor 350 (AF350) carboxylic acid, succinimidyl ester
(Molecular Probes, Eugene, OR) with the ε-amines of lysine residues following the
manufacturer’s instructions. Briefly, SAX-purified Fc was diluted to 2 mg/mL using
appropriate volumes of reaction buffer A (100 mM sodium bicarbonate, 50 mM sodium
phosphate, 50 mM NaCl ) and reaction buffer B (1,000 mM sodium bicarbonate, 50 mM
sodium phosphate, 50 mM NaCl) to achieve a final buffer composition of 100 mM sodium
bicarbonate, 50 mM sodium phosphate, 50 mM NaCl, pH 8.0. Subsequently, AF350 was
dissolved in water (10 mg/mL) and immediately mixed with SAX-purified Fc at molar ratios
of 0:1, 2.5:1, 5:1, 7.5:1 and 15:1 (dye-to-Fc ratio). The reaction proceeded for 1 h at ambient
temperature under constant gentle stirring. Excess dye was subsequently removed by
dialysis against phosphate buffer (50 mM sodium phosphate, 50 mM NaCl at pH 7.3) at 4
°C for 72 h using 10K MWCO Slide-a-lyzer dialysis cassettes (Pierce, Rockford, IL). The
resulting dye-to-antibody ratio (DAR) was determined by direct measurement of the protein
absorbance at 280 nm and dye absorbance at 346 nm and calculated using the following
equation:
(Eqn.1)
where = extinction coefficient of Fc at 280 nm (71,570 M−1 cm−1),  = extinction
coefficient of AF350 at 280 nm (3,610 M−1 cm−1), = extinction coefficient of Fc at 346
nm (determined to be negligible by relative UV absorbance measurement and therefore
assumed to be zero), = extinction coefficient of AF350 at 346 nm (19,000 M−1 cm−1),
and R = A346 / A280 = the 346 nm to 280 nm absorbance ratio 13. Subsequently, Fc-
conjugates were diluted to 1 mg/mL in phosphate buffer (50 mM sodium phosphate, 50 mM
NaCl at pH 7.3) and stored at 4 °C.
Characterization of Fc and Fc-conjugates
Gel Electrophoresis: SDS-PAGE analysis was performed in NuPAGE 12% Bis-Tris
precast gels with MOPS running buffer (Invitrogen, Carlsbad, CA). Analysis of IgG1 Fc and
Fc-conjugates using reducing SDS-PAGE analysis resulted in two distinct bands. The higher
intensity band corresponds to glycosylated protein (92%) and the less intense band to
aglycosylated (8%) protein (Figure S2, Supporting Information).
Isoelectric focusing (IEF) was performed with Novex® pH 3-10 precast IEF gels
(Invitrogen). The gels were stained with Novex Colloidal blue staining kit according to the
manufacturer’s instructions. The stained gels were imaged using a GS-800 calibrated
densitometer and analyzed with Quantity One Software (Bio-Rad Laboratories, Hercules,
CA).
Size Exclusion (SE)-UPLC: Approximately 1 μg of protein was loaded onto an
ACQUITY™ BEH125 SEC column (4.6 × 150 mm, 1.7 um; Waters Corporation)
equilibrated at 30 °C. All ultra performance liquid chromatography (UPLC) separations
were performed on a Waters ACQUITY™ H-Class BIO system (Milford, MA) equipped
with tunable ultraviolet (TUV) and fluorescence detectors. Isocratic separation was
performed (flow rate = 0.3 mL/min) with a mobile phase consisting of phosphate buffer (50
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mM sodium phosphate, 50 mM NaCl, pH 7.3). The column effluent was monitored by UV
detection at 280 and 346 nm and fluorescence detection at 346 nm (ex.) and 442 nm (em.).
Strong Anion Exchange (SAX)-UPLC: Approximately 10 μg of protein was loaded onto a
Bio SAX-NP3 column (4.6 × 50 mm, 3 um; Agilent Technologies) equilibrated at 30 °C.
Gradient separation was achieved (flow rate = 0.5 mL/min) with an initial hold at 99% A (10
mM Tris HCl, pH 9.0), 1% B (10 mM Tris HCl, 1 M NaCl, pH 9.0) for 3 min, followed by
38% A, 62% B over 67 min, 1% A, 99% B over 5 min, then 99% A and 1% B over 1 min,
which was then maintained for 4 min to re-equilibrate the column. The column effluent was
monitored by UV detection at 280 and 346 nm and fluorescence detection at 346 nm (ex.)
and 442 nm (em.).
Liquid Chromatography Electrospray Mass Spectrometry (LC-ESI-MS): The ESI-MS
system was an Applied Biosystems 4000 QTrap equipped with an electrospray ionization
source (Applied Biosystems, Foster city, CA). The instrument was operated in positive ion
mode and scanned from 1190 to 1470 m/z. The mass accuracy and resolution of the method
were < 100 ppm and 1200, respectively. The tandem mass spectrometer (MS/MS) system
was coupled to two LC-20AD pumps with in-line CBM-20A controller and DGU-20A5
solvent degasser (Shimadzu, Kyoto, Japan) and a LEAP CTC HTS PAL autosampler (CTC
Analytics, Carrboro, NC).
To simplify the mass spectrum, samples were deglycosylated and reduced prior to analysis.
Deglycosylation was performed by incubating 50 μg of sample with 1.25 U of N-
glycosidase F (EMD Millipore, Billerica, MA) at room temperature overnight. The samples
were subsequently reduced with 20 mM dithiothreitol (DTT) at 37 °C for 1 h.
Approximately 10 ug of deglycosylated, reduced sample was loaded onto an Agilent Zorbax
SB-C8 HPLC column (4.6 × 150 mm, 3.5 um) equilibrated at 40 °C. Gradient separation
was achieved (flow rate = 1 mL/min) with an initial hold at 95% A (0.1% formic acid in
water), 5% B (0.1% formic acid in acetonitrile) for 1 min, followed by 5% A, 95% B over 3
min, hold at 5% A, 95% B for 2 min, then back to 95% A, 5% B over 3 min, which was then
maintained for 3 min to re-equilibrate the column. Due to protein carryover, the column was
washed between runs and at least one blank injection was performed between any two
consecutive protein injections.
Peak assignments were performed by comparison of theoretical and observed mass-to-
charge ratios in the range of 1190 to 1470 m/z (Tables S1-S4, Supporting Information). The
protein sequence and glycosylation states were identified under reducing conditions, with
and without PNGase F treatment, via LC-ESI-MS (data not shown). Multiple peaks were
observed that correspond to aglycosylated and high-mannose Fc glycoforms, in good
agreement with previous reports 10. Characterization of deglycosylated and reduced Fc-
conjugates by LC-ESI-MS resulted in the identification of peaks corresponding to Fc heavy
chain conjugated with 0 – 8 AF350 molecules (threshold set at 3.0 × 104 cps) (Figure S3A-
D, Supporting Information). With the exception of Fc heavy chain peaks in the 20+ charge
state, the mass spectra were complicated by peak overlap between neighboring charge states
(e.g. overlap of peaks corresponding to Fc heavy chain conjugates with 4 and 0 AF350
molecules in the 22+ and 21+ charge states, respectively). Thus, only peaks corresponding
to Fc heavy chain in the 20+ charge state were used for quantitative analysis.
Statistical analysis: All statistical analyses were performed using SPSS statistical software,
version 18.0 (SPSS Inc., Chicago, IL). The Pearson product-moment correlation coefficient
(r) was used to determine the linear dependence between variables. Differences were
considered to be statistically significant at a level of P < 0.05.
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Purification and characterization of IgG1 Fc
To evaluate the effects of chemical conjugation on the charge properties of Fc-conjugates,
the charge heterogeneity of IgG1 Fc was assessed prior to chemical conjugation with
AF350. Analysis of protein G affinity-purified Fc using non-reducing, non-denaturing
isoelectric focusing (IEF) revealed the presence of five bands, including two acidic and two
basic Fc isoforms (Figure 1). The most prominent band has an isoelectric point (pI) of
approximately 7.7 +/− 0.07, which is 0.6 units greater than the theoretical value calculated
from the protein sequence (Table S5, Supporting Information). This level of heterogeneity
would complicate the Fc-conjugate charge profile and mask effects due to chemical
conjugation. To reduce the number of charge variants, IgG1 Fc was further purified using
SAX-HPLC and determined by IEF to consist of a single charge species with a pI of
approximately 7.7 (Figure 1). LC-MS confirmed that the major band corresponds to native
Fc. The yield of SAX-purified Fc was ~ 68%. This is in good agreement with IEF band
analysis of protein G affinity-purified Fc, which contained ~ 68 % native Fc as determined
by densitometry.
Analysis of average dye-to-antibody ratio (DAR)
An important factor influencing the efficacy and stability of immunoconjugates is the
average number of drug molecules covalently attached to the protein carrier. The average
dye-to-antibody ratio (DAR) was determined using UV/VIS spectroscopy. Figure 2 shows
the normalized absorption spectra of the Fc-conjugates at various labeling densities. With
increasing DAR, the absorption band of IgG1 Fc at 280 nm decreases relative to the
absorption band of the AF350 at 346 nm. Using the extinction coefficients for Fc and AF350
at their absorption maxima, the average DARs are 0, 1.5, 2.8, 4.9 and 7.8 (Table 1). This
range encompasses the typical DAR values encountered in ADCs; in general, a DAR of 2 –
4 results in the best therapeutic window 13-15.
The average DAR was also determined by integrating the absorbance during SE-UPLC
chromatographic separation (Figure 3). Using Eqn. 1 and by taking the ratio of the area
under the curves (346 to 280 nm), the average DARs were in good agreement with results
obtained using the cuvette-based method (Table 2). Additionally, SE-UPLC also allows for
the detection of protein aggregates and low molecular weight impurities, which can result in
undesirable immunogenicity and/or decreased efficacy 16. Analysis of peak shape and
elution time indicated no soluble Fc aggregates were present and samples contained less
than 5% unconjugated dye. Although these techniques enable accurate measurement of the
average properties of immunoconjugates, both approaches lack the ability to probe
heterogeneity among the conjugates.
To begin to characterize the individual DAR components of the Fc-conjugate pool, LC-ESI-
MS was used as an orthogonal method. First, the average DAR values were examined and
compared to the values derived from the absorbance methods. Mass peaks corresponding to
Fc heavy chain conjugated with 0 – n AF350 molecules were detected for each sample
(Figure S3A-D and Tables S1-S4, Supporting Information). To account for the potential
change in ionization properties of the conjugate relative to the naked protein and between
different conjugate species, the quantitative analysis of ADCs by ESI-MS should include all
of the charge states for each conjugate species 17. However, due to the inability to resolve
overlapping peaks between neighboring charge states (e.g. overlap of peaks corresponding
to Fc heavy chain conjugates with 4 and 0 AF350 molecules in the 22+ and 21+ charge
states, respectively) it was not possible to definitively quantify the individual conjugate
species in all of the charge states. Therefore, the average DAR was estimated by integration
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of the peaks corresponding to Fc heavy chain in 20+ charge state. Assuming equivalent
recovery and ionization of all species, the average DAR was calculated according to the
following equation:
(Eqn.2)
where n equals the number of AF350 molecules per Fc chain and An is the peak area
corresponding to the species with n AF350 molecules per Fc chain 17. The average DAR
determined from MS data was within 8% of the UV-based approaches, with the exception of
Fc-conjugate DAR 1.4 which was within 12% (Table 2). Similar results were obtained from
MS data collected in the range of 1380 – 1660 m/z for the resolvable 17+ and 18+ charge
states, but peak overlap prevented quantitation of all charge states (data not shown).
Together, these results indicate that the current LC-ESI-MS analytical method, while not
highly accurate, reasonably estimates the average DAR of Fc-conjugates.
Analysis of individual DAR species by mass spectroscopy
In addition to average DAR, characterizing the distribution of individual DAR species is
important because different forms may have different behaviors, including stability, PK and
toxicity profiles 13. Analysis of deglycosylated and reduced Fc-conjugates by LC-ESI-MS
shows a wide distribution of the number of AF350 molecules conjugated to each Fc chain.
The relative abundance of each species (Χn) was calculated according to the following
equation:
(Eqn.3)
where n equals the number of AF350 molecules per Fc heavy chain, Χn is the fraction of
heavy chains molecules conjugated with n number of AF350 molecules per chain, and An is
the peak area corresponding to that species. Because a normal distribution of DAR species is
expected to result from the chemistry, the DAR distribution of intact Fc-conjugates was
predicted using probability theory and the relative abundance of each individual DAR
species was compared. As shown in Figure 4, the predicted DAR distributions for intact Fc-
conjugates are plotted along with corresponding normal distributions. As expected, an
increase in the average DAR resulted in an increase in the number of individual DAR
species (r = 0.986), which is consistent with the normal probability distribution function.
The dependence of heterogeneity on average DAR is also described by the full width at half
maximum (FWHM) for each DAR distribution, which increased with increasing average
DAR (Table 2). Together these data indicate the expected range and proportion of individual
DAR species produced for each sample (Figure 4).
Charge analysis by IEF and SAX-UPLC
Prior to SAX purification, charge-based analysis of IgG1 Fc resulted in the presence of
native Fc along with two acidic and two basic isoforms. The shift in pI for the two acidic
bands observed at 7.4 and 7.1 corresponds to the theoretical shift in pI upon deamidation of
one and two asparagine (Asn) residues, respectively. This is expected because the protein
sequence contains two Asn-Gly motifs that are highly susceptible to deamidation 18. The
basic isoforms may be attributed to other post-translational modifications such as oxidation,
isomerization, and formation of succinimide intermediate during deamidation 4. In general,
this level of charge heterogeneity is typical of commercially prepared
biotherapeutics 5, 19-21. Here, these degradation products were effectively removed by SAX,
permitting analysis of how conjugation affects charge behavior.
Chemical conjugation, particularly when linking to lysine residues, modifies the electrostatic
properties of the Fc protein surface. Thus, the electrostatic properties of Fc-conjugates were
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assessed using IEF. Despite starting with homogenous SAX-purified Fc, IEF analysis of the
Fc-conjugate DAR 0 (mock reaction) had a small proportion (0.9%) of an additional acidic
band. This band likely corresponds to deamidated Fc, which forms spontaneously during
storage in near neutral conditions (Figure 1). In this study, conditions were controlled
carefully to limit the extent of deamidation in the conjugate samples to below or near the
limit of detection of the methods used to eliminate interference and focus on changes
resulting from attachment of AF350.
Chemical conjugation with AF350 resulted in a reduction in the pI of conjugated versus
unconjugated species. Due to the decrease in pI upon conjugation, the amount of
unconjugated versus conjugated protein is readily quantified by IEF analysis. The
percentage of naked Fc in Fc-conjugates DAR 1.5 and DAR 2.8 was 21.6 and 5.3%,
respectively; whereas, no naked Fc was detected in Fc-conjugates DAR 4.9 and DAR 7.8. In
general, Fc-conjugates displayed a very complex pI profile. If the distribution of DAR
species was the only factor determining the charge properties upon conjugation, then only 6
additional bands corresponding to DAR 1 – 6 (DAR 7 and 8 are below the IEF limit of
detection) would be expected for Fc-conjugate DAR 1.5. However, approximately 14
additional bands were observed for Fc-conjugate DAR 1.5 by IEF (Figure 1), indicating that
DAR distribution is not the sole factor influencing the charge properties.
Above pH = 3.8, AF350 carries a net negative charge due to the presence of a sulfonate
group. Therefore, conjugation of AF350 to the ε-amine of lysine is expected to reduce the
net charge by two at neutral pH. The theoretical pIs for Fc-conjugates with 0 – 8 AF350
molecules were estimated by substituting aspartic acid for lysine within the protein sequence
and inputting the sequence into the ProtParam tool (ExPaSy Server) (Table S5, Supporting
Information). Because native Fc displays a pI that differs substantially from the theoretical
value, addition of a correction factor of 0.6 was applied to account for the difference. The
estimated pI for Fc-conjugated with 1-AF350 molecule is 7.2, which corresponds to the
most intense band present in Fc-conjugate DAR 1.5 at pI 7.1. Interestingly, the pI of the
third most intense band for Fc-conjugate DAR 1.5 is 6.7, which approximately corresponds
to the predicted pI of 6.9 for Fc-conjugated with 2-AF350 molecules. Analysis of the IEF
lane profile for Fc-conjugate DAR 1.5 shows the presence of two additional bands (pI ~ 7.3
and 7.0) that are adjacent to the major DAR 1 band and two additional bands (pI ~ 6.8 and
6.6) that are adjacent to the major DAR 2 band (Figure 1). Although the band at pI ~ 7.3
migrates with the deamidated Fc band observed in the mock reaction, the relative abundance
of the individual deamidated species after the conjugate reaction are below the limit of
detection, indicating this band instead results from AF350 attachment. Assuming these
neighboring bands represent charge variants with the same number of attached dye
molecules, the total relative abundance of DAR 1 and DAR 2 is 33% and 25%, respectively,
which is in good agreement with the DAR distribution determined by mass spectrometry.
For DAR 1, the major band at pI 7.1 constitutes 68% of the DAR 1 species, while the less
intense bands at pI 7.3 and 7.0 represent 15% and 17% of the total subpopulation,
respectively. Similarly, 52% of DAR 2 has a pI of 6.7, and the bands at pI 6.8 and 6.6
represent 19% and 29% of the DAR 2 conjugates, respectively. IEF analysis of Fc-conjugate
DAR 2.8 resulted in the identification of 19 bands corresponding to species conjugated with
1 – 8 AF350 molecules (DAR 9 and 10 are below the IEF limit of detection). As the average
DAR increased to 4.9 and 7.8, there was a shift in the band intensities to more acidic charge
variants (higher DAR species). In general, the theoretical pIs (with applied correction factor)
agreed well with the observed values for bands corresponding to Fc-conjugate DAR 1 and 2.
Above DAR 2, the observed pIs could not be identified using this approach. In addition, the
relative quantities of Fc-conjugates DAR 1-2 were in good agreement with the DAR
distribution predicted by mass spectrometry. However, due to substantial band overlap, the
number of resolvable individual IEF bands decreased as the average DAR increased from
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2.8 to 7.8. Positional isomers likely account for the high charge heterogeneity. Assuming all
38 lysine residues are available for conjugation, for example, using the binomial coefficient
there are more than 103 and 107 positional isomers for attachment of 3 and 8 molecules,
respectively, to Fc. The actual number of isoforms is greatly expanded because a range of
DARs is present. Despite the high heterogeneity, the majority of Fc-conjugate species show
similar charge properties. It is, however, evident in the average DAR 1.5 and 2.8 samples
that a few distinct subpopulations emerge for an individual DAR, which indicates not every
conjugate behaves in the same manner. Fc-conjugates species with higher average DAR
exhibit a more complex spectrum of charge properties, and identification of the individual
species is hindered by decreased resolution. As a result, we were unable to assign DAR
values to the more acidic bands corresponding to Fc-conjugates with DAR ≥ 3.
In addition to IEF analysis, SAX-UPLC was used as an orthogonal method to assess the
electrostatic properties of Fc-conjugates. The elution of Fc and Fc-conjugated species were
monitored by UV absorbance at 280 nm; whereas conjugate and unconjugated AF350
species were monitored by UV absorbance at 346 nm and fluorescence emission. Analysis
of Fc-conjugate DAR 0 (mock reaction) resulted in a single peak that eluted at 13 min
(Figures S4A, Supporting Information). Unlike IEF, no additional peak corresponding to
deamidated Fc was observed, because the UV signal intensity was below the limit of
detection. As expected, chemical conjugation with AF350 increased the retention time of
Fc-conjugated species due to increased interaction between the anionic AF350 molecules
and the cationic column packing material (Figure 5). In general, Fc-conjugates displayed
very complex peak profiles by SAX-UPLC. Although, baseline resolution of each variant
was not achievable, we were able to identify peaks based on the relative contributions from
protein and AF350 signals. Thus, the amount of unconjugated versus conjugated protein was
readily quantified by SAX-UPLC. The percentage of naked Fc in DAR 1.5 and DAR 2.8
samples was 22% and 3.6%, respectively; whereas, no naked Fc was detected in DAR 4.9
and DAR 7.8 samples. These values are in good agreement with the IEF analysis. The peak
corresponding to unconjugated AF350 was identified at 16 min (Figures S4B, Supporting
Information) and was determined to be less than 5% of the total UV 346 nm peak area for
Fc-conjugates, in agreement with SE-UPLC analysis. Additionally, each peak was assigned
a DAR value using Eqn. 1 by taking the ratio of the baseline-corrected UV 346 nm and UV
280 nm channels. For Fc-conjugate DAR 1.5, peaks corresponding to Fc conjugated with 0
to 2 AF350 molecules were observed; those with larger DARs were below the limit of
detection. For species with DAR < 3, multiple peaks are apparent. Based on the absorbance
ratio, 3 peaks in the fluorescence trace were identified that correspond to DAR 1 (Figure 5).
Due to significant overlap among Fc-conjugate species with DAR > 2, it was difficult to
resolve individual species. This is not surprising, because the site of conjugation and
orientation of the conjugated AF350 molecule likely influence the resulting interaction
between the conjugate and column matrix. Regardless, the increased sensitivity afforded by
fluorescence detection identified the presence of low abundance species that eluted later and
likely correspond to Fc-conjugates with DARs of 3 – 8, which were observed using MS.
Similarly, SAX-UPLC analysis of Fc-conjugate DAR 2.8 resulted in peaks corresponding to
Fc conjugated with 0 to 4 AF350 molecules before the UV signal intensities dropped below
the limit of detection (Figure S4C, Supporting Information). As the average DAR increased
to 4.9 and 7.8, there was a further shift in the elution time and increased peak overlap, likely
due to an increase in the number of DAR species and charge variants (Figures S4D and S4E,
Supporting Information). Comparison of the absorbance ratios provides confirmation that a
range of charge behaviors emerge among individual DAR subpopulations.
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The electrostatic properties of a protein, including pI and charge distribution, are critical
parameters that influence protein behaviors such as thermal stability 22-24 and
viscosity 25-26, and as such, it is important to assess the charge properties of protein
therapeutics, including immunoconjugates. In the present study, we sought to characterize
the effects of attaching AF350 to IgG1 Fc on electrostatic properties of the resulting Fc-
conjugates. Charge-based methods of analysis, such as IEF and SAX-UPLC, are capable of
probing the underlying complexities within immunoconjugate drug products. Despite the
utility of these methods, there are only a few published reports of charge-based assays
applied to immunoconjugates 9, 27-29. This may be in part because of high charge
heterogeneity of conjugates, since charge variants may arise spontaneously due to chemical
degradation and as a result of modification. Here, isolation of the native, single-charge
variant of Fc was performed to simplify analysis and examine the effects of chemical
conjugation on the observed charge of Fc using IEF and SAX-UPLC. Using this approach,
we demonstrated the existence of multiple charge variants within a single DAR.
The choice of chemistry used to link the protein carrier and payload is critical for the
success of immunoconjugates 30. Conjugation strategies often involve reaction to solvent
accessible lysine residues 30. A number of ADCs undergoing late-stage clinical trials utilize
lysine-based linker chemistries and include Trastuzumab emtansine 3 and Inotuzumab
ozogamicin 31. Due to favorable reaction kinetics and stability of the resulting amide bond,
chemical cross-linking reactions commonly use succinimidyl ester chemistry to react with
the ε-amine of lysine residues 30. Therefore, we used a succinimidyl ester of AF350 to react
with the ε-amine of lysine residues. Based on the protein sequence, 38 lysines are
theoretically available for conjugation. Due to the random nature of chemical conjugation
with solvent accessible lysine residues 17, 32, it was anticipated that the resulting Fc-
conjugates would consist of a complex mixture of species that differ in both the number of
conjugated AF350 molecules and sites of covalent attachment, consistent with a normal
distribution.
We anticipated that the number of dye molecules attached, rather than the site of attachment
to Fc would dictate the overall charge of the conjugate, and therefore would be predictable.
The results of the SAX and IEF analyses, however, indicate that more than one charge state
exists for individual Fc-conjugates having the same DAR. This is most easily observed in
the sample with lowest average DAR (1.5). Comparison of the absorbance intensities of the
protein and dye for a given SAX peak demonstrates attachment of a single dye molecule
results in more than one peak position. This reflects a difference in the overall charge
behavior of individual conjugates and suggests some site(s) of attachment may have an
additional influence on electrostatic properties of the conjugate. This is also observed when
two or more dye molecules are attached, but the analysis becomes more complex as
crowding decreases resolution and combinations of individual DARs may overlap.
Similarly, IEF analysis of Fc-conjugates resulted in additional bands, indicating that DAR is
not the only factor influencing the charge behavior. Thus, the local protein environment,
which is known to influence the pKa of resident amino acids, may perturb a network of
charge-based interactions on Fc and/or influence the pKa of conjugated AF350. The
importance of context surrounding a charged moiety was highlighted in the classical work of
Tanford et al. 33-35. Furthermore, chemical conjugation may indirectly affect the pI through
alteration of the higher order protein structure. Therefore, the high charge heterogeneity is
likely due to a combination of the DAR distribution and site of conjugation.
Another important parameter for therapeutic immunoconjugates is the average number of
drug molecules covalently attached to the protein carrier 17. Multiple methods, including UV
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absorbance spectrophotometry and mass spectrometry, were used to measure the average
DAR values. In general, these orthogonal methods resulted in comparable average DAR
values. Although we did not expect MS quantification of DAR to be highly accurate due to
peak overlap which prevented analysis of all charge states, the distribution of individual
DAR species were reasonably estimated. The range of individual DAR species increased
with average DAR and is likely a direct result of the choice of reaction chemistry which is
relatively non-specific due to the availability of ~ 38 reaction sites per Fc protein.
Approximately 70% of the DAR 1 species behaved as expected, but interestingly, 30% of
protein with DAR 1 did not. Two additional charge behaviors were observed for DAR 1.
This trend was detected for DAR 2 as well. Although species with DAR greater than 2 were
not quantified due to insufficient resolution, the combined SAX, IEF and MS analyses
indicate the trend continues because the charge behavior is more complex than predicted by
DAR alone.
Although further studies are required to characterize the positions at which conjugation
alters the charge behavior of Fc, it is reasonable to hypothesize that partially exposed lysine
residues involved in electrostatic interactions are most likely responsible because neither
protein loss nor aggregates were observed. Conjugation with these lysine residues could
alter the conformation of the protein and/or expose previously paired, negatively charged
residues, which would shift the pI to a slightly more acidic value than when an unpaired
lysine is modified. Because the measured pI is substantially more basic than predicted from
the sequence, even a modest conformational change could perturb the synergy of the
electrostatic network, likely resulting in a shift toward a more acidic pI. Alternatively, a
specific salt bridge could be broken. As noted by Liu et al. the crystal structure of human
IgG1 Fc 36 reveals direct hydrogen bonding between K29 and E161 in the CH2-CH3 hinge
region 37. Modification of this surface accessible lysine would leave the carboxylate without
a binding partner. Similarly, Gunasekaran et al. identified a pair of peripherally located
charged residues (K409-D399) at the interface of the CH3 domains 38. In this case, K409 is
not completely buried but is less surface accessible than K29. Breaking the electrostatic
association at this site would alter the domain-domain interface and increase exposure of the
anionic partner. These two types of interactions likely affect the pI to different extents
because of differences in packing and could potentially explain the observation of two
subpopulations of charged states for DAR 1.
A lack of understanding and control of conjugation site can lead to charge heterogeneity,
which affects pharmaceutical and biopharmaceutical properties as well as efficacy. The
effects of charge heterogeneity on the thermal stability, solubility and viscosity of mAbs are
well documented 22-26 and have established the need for the detection of and
implementation of measures to control charge properties that affect critical quality attributes.
Such studies have not yet been reported for ADCs. To better inform discovery and ensure
product integrity, further studies are required to understand the factors responsible for the
impact of charge heterogeneity of ADCs. Follow up studies, including purification of
individual Fc-conjugate charge variants and subsequent peptide mapping analysis is
expected to reveal the specific conjugation sites responsible for the observed charge
heterogeneity.
Conclusions
It is known that lysine-based conjugation results in a highly heterogeneous mixture of
molecules, which vary in the distribution of DAR and site of attachment. Here, we provide
evidence that the position at which a small molecule is attached to Fc protein affects the
overall charge of the conjugate, independent of DAR. Subpopulations were observed for
species having the same number of conjugated molecules that differ in their overall charge.
Boylan et al. Page 10













This led to greater heterogeneity in the electrostatic properties of the conjugates than would
be expected based solely on the number of lysine residues modified. As has been shown
with mAbs, electrostatics properties affect stability, solubility and viscosity of proteins. As
such, the ability to characterize charge properties of ADCs is important for evaluating their
performance characteristics and to reliably generate stable, well-behaved protein-drug
conjugates.
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Abbreviations
ADC antibody-drug conjugate
AF350 Alexa Fluor 350
DAR dye-to-antibody ratio
HPLC high performance liquid chromatography
IEF isoelectric focusing
IgG1 Fc Fragment crystallizable region of immunoglobulin G subtype 1




SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis
SE size-exclusion
UPLC ultra performance liquid chromatography
UV ultraviolet
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IEF analysis of IgG1 Fc and Fc-conjugates. Lanes: 1) Protein G affinity-purified IgG1 Fc, 2)
SAX-purified IgG1 Fc, and Fc-conjugates 3) DAR 0, 4) DAR 1.5, 5) DAR 2.8, 6) DAR 4.9,
and 7) DAR 7.8. The isoelectric point (pI) for the labeled bands were identified using
SERVA IEF marker 3-10 from Invitrogen. 58×42mm (600 × 600 DPI)
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UV spectra of Fc-conjugates prepared at various DARs, normalized to absorbance at 280
nm. Overlay shows a proportional increase in 346 nm absorbance as the amount of
conjugated AF350 increases. 59×43mm (600 × 600 DPI)
Boylan et al. Page 15














Analysis of native Fc-conjugate DAR 7.8 via SE-UPLC with UV absorbance detection at
280 and 346 nm. Labeled peaks correspond to unconjugated AF350 and Fc-conjugates.
100×77mm (300 × 300 DPI)
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Distribution of DAR species. Symbols represent the relative abundance of each individual
DAR species as determine by LC-ESI-MS analysis of reduced and deglycosylated Fc-
conjugates. The diamonds (red), squares (orange), triangles (green), and circles (blue)
represent Fc-conjugates with average DAR 1.5, 2.8, 4.9 and 7.8, respectively. Solid lines in
the same color represent the theoretical normal distribution for the corresponding average
DAR. 60×46mm (300 × 300 DPI)
Boylan et al. Page 17














Analysis of Fc-conjugate DAR 1.5 via SAX-UPLC. Overlay of individual 280 and 346 nm
absorbance traces (top) and fluorescence detected at 442 nm (bottom) are shown. Shaded
areas represent unconjugated AF350 and Fc-conjugates with calculated dye-to-antibody
ratio derived from measured absorbance at 346 nm (dye) and 280 nm (Fc). 100×60mm (300
× 300 DPI)
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species c Yield, % 
d Purity, % e
2.5 1.5 ± 0.02 0 - 8 83 99.9
5 2.8 ± 0.04 0 - 10 89 98.6
7.5 4.9 ± 0.05 0 - 12 86 99.5
15 7.8 ± 0.01 2 - 16 86 97.4
a
Stoichiometric ratio of Alexa Fluor 350 to Fc protein during conjugation reaction.
b
Average dye-to-antibody ratio (DAR) as determined by UV/VIS spectroscopy. Data represents the average +/− SD (n=2).
c
Range of dye-to-antibody ratios observed for Fc-conjugates as determined by LC-ESI-MS analysis of deglycosylated and reduced protein
samples.
d
Yield of Fc-conjugates post dialysis against phosphate buffer at 4° C for 72 h using 10K MWCO slide-a-lyzer dialysis cassettes.
e
Percentage of conjugate dye (as compared to free dye) as determined by SE-UPLC analysis with fluorescence detection.
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Table 2
Comparison of average dye-to-antibody ratios measured by various methods.
DAR via UV-VIS a
DAR via SE-UPLC
(AUC) a
DAR via LC-MS FWHM b
1.5 ± 0.02 1.4 ± 0.01 1.6 3.1
2.8 ± 0.04 2.8 ± 0.02 3.0 4.3
4.9 ± 0.05 4.8 ± 0.02 5.1 5.0
7.8 ± 0.01 7.7 ± 0.02 8.3 5.3
a
Data represents the average +/− SD (n=2).
b
Full width at half maximum (FWHM) obtained from the DAR distributions shown in Figure 4.
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